These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides]. Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009 [TBL] [Abstract][Full Text] [Related]
4. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Elmaagacli AH; Beelen DW; Schaefer UW Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277 [TBL] [Abstract][Full Text] [Related]
6. The management of chronic myeloid leukaemia--a case history. Sureda A; Hernández-Bronchud M Ann Oncol; 1997 Jan; 8(1):91-6. PubMed ID: 9093713 [No Abstract] [Full Text] [Related]
7. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia]. Liu J; Jiang J; Zhang Y; Wu D; Yang G; Huang X; Wei X Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):599-601. PubMed ID: 12528561 [TBL] [Abstract][Full Text] [Related]
8. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise? de Fabritiis P; Calabretta B Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496 [No Abstract] [Full Text] [Related]
9. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells. Rapozzi V; Cogoi S; Xodo LE Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454 [TBL] [Abstract][Full Text] [Related]
11. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370 [TBL] [Abstract][Full Text] [Related]
12. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia]. Etienne G; Mahon FX Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816 [TBL] [Abstract][Full Text] [Related]
13. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747 [TBL] [Abstract][Full Text] [Related]
14. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167 [TBL] [Abstract][Full Text] [Related]
15. Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results. Alimena G; Meloni G; de Cuia MR; Rondinelli MB; Lo Coco F; Montefusco E; Mancini M; Pinto R; Nanni M; Cedrone M Leuk Lymphoma; 1993; 11 Suppl 1():281-91. PubMed ID: 7902746 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center. Kantarjian HM; Talpaz M Leuk Lymphoma; 1993; 11 Suppl 1():169-74. PubMed ID: 8251891 [No Abstract] [Full Text] [Related]